CDC and most other western Disease response organisations have now issued level 3 travel warning for most of West Africa.
The highest level alert (Level 4) is now being considered on a daily monitoring basis as this is now officially the biggest and worst Ebola outbreak since records began:
As of 31st July of 1323 reported cases, 739 have died.
As of yesterday, most large corporations started issuing travel bans on their staff travelling to or from the region.
Ebola is spread by contact, or contaminated food (more often than not so called 'bushmeat' the types of which are regularly illegally smuggled into Europe).
How do we grade our advisories?
Travel advisories are graded across four different levels. The level we give a specific country reflects our overall assessment of the security situation in the destination and is designed to help you assess the level of risk you would face in that country.
In determining the level of a destination we consider the security risks and compare these to the general security threats in a large Australian city, but there is no strict formula. We also take into account the capacity of a foreign government to deal with the risks.
Level 1 – Exercise normal safety precautions
Exercise common sense and look out for suspicious behaviour.
Level 2 – Exercise a high degree of caution
Pay close attention to your personal security at all times and monitor the media about possible new safety or security risks.
Level 3 – Reconsider your need to travel
There is a high level of risk in the country/area. This may be due to a very high threat of terrorist attack or a volatile and unpredictable security or medical situation. If you are already in a destination where we advise you to "reconsider your need to travel" and you are concerned about the situation, you should consider leaving.
Level 4 – Do not travel
The security or medical situation is extremely dangerous. This may be due to a very high threat of terrorist attack, widespread armed conflict and or dangerous levels of violent crime. If you are already in a destination where we advise that you "do not travel" you should consider leaving unless you have compelling reasons to stay.
Each travel advisory is graded against the levels outlined above; this is shown in a coloured bar at the top of the summary section of each travel advisory. Some advisories show more than one level. This may occur when the overall country is at a certain level, but different regions within the country are assessed to be at higher or lower levels due to particular risks or safety concerns.
Key facts
Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans.
EVD outbreaks have a case fatality rate of up to 90%.
EVD outbreaks occur primarily in remote villages in Central and West Africa, near tropical rainforests.
The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
Fruit bats of the Pteropodidae family are considered to be the natural host of the Ebola virus.
Severely ill patients require intensive supportive care. No licensed specific treatment or vaccine is available for use in people or animals.
Ebola first appeared in 1976 in 2 simultaneous outbreaks, in Nzara, Sudan, and in Yambuku, Democratic Republic of Congo. The latter was in a village situated near the Ebola River, from which the disease takes its name.
Genus Ebolavirus is 1 of 3 members of the Filoviridae family (filovirus), along with genus Marburgvirus and genus Cuevavirus. Genus Ebolavirus comprises 5 distinct species:
Bundibugyo ebolavirus (BDBV)
Zaire ebolavirus (EBOV)
Reston ebolavirus (RESTV)
Sudan ebolavirus (SUDV)
Taï Forest ebolavirus (TAFV).
BDBV, EBOV, and SUDV have been associated with large EVD outbreaks in Africa, whereas RESTV and TAFV have not. The RESTV species, found in Philippines and the People’s Republic of China, can infect humans, but no illness or death in humans from this species has been reported to date.
Transmission
Ebola is introduced into the human population through close contact with the blood, secretions, organs or other bodily fluids of infected animals. In Africa, infection has been documented through the handling of infected chimpanzees, gorillas, fruit bats, monkeys, forest antelope and porcupines found ill or dead or in the rainforest.
Ebola then spreads in the community through human-to-human transmission, with infection resulting from direct contact (through broken skin or mucous membranes) with the blood, secretions, organs or other bodily fluids of infected people, and indirect contact with environments contaminated with such fluids. (The use of public toilets are thought to be one at risk vector).
Burial ceremonies in which mourners have direct contact with the body of the deceased person can also play a role in the transmission of Ebola. Men who have recovered from the disease can still transmit the virus through their semen for up to 7 weeks after recovery from illness.
Health-care workers have frequently been infected while treating patients with suspected or confirmed EVD. This has occurred through close contact with patients when infection control precautions are not strictly practiced.
Among workers in contact with monkeys or pigs infected with Reston ebolavirus, several infections have been documented in people who were clinically asymptomatic. Thus, RESTV appears less capable of causing disease in humans than other Ebola species.
However, the only available evidence available comes from healthy adult males. It would be premature to extrapolate the health effects of the virus to all population groups, such as immuno-compromised persons, persons with underlying medical conditions, pregnant women and children. More studies of RESTV are needed before definitive conclusions can be drawn about the pathogenicity and virulence of this virus in humans.
Signs and symptoms
EVD is a severe acute viral illness often characterized by the sudden onset of fever, intense weakness, muscle pain, headache and sore throat. This is followed by vomiting, diarrhoea, rash, impaired kidney and liver function, and in some cases, both internal and external bleeding. Laboratory findings include low white blood cell and platelet counts and elevated liver enzymes.
People are infectious as long as their blood and secretions contain the virus. Ebola virus was isolated from semen 61 days after onset of illness in a man who was infected in a laboratory.
The incubation period, that is, the time interval from infection with the virus to onset of symptoms, is 2 to 21 days.
Diagnosis
Other diseases that should be ruled out before a diagnosis of EVD can be made include: malaria, typhoid fever, shigellosis, cholera, leptospirosis, plague, rickettsiosis, relapsing fever, meningitis, hepatitis and other viral haemorrhagic fevers.
Ebola virus infections can be diagnosed definitively in a laboratory through several types of tests:
antibody-capture enzyme-linked immunosorbent assay (ELISA)
antigen detection tests
serum neutralization test
reverse transcriptase polymerase chain reaction (RT-PCR) assay
electron microscopy
virus isolation by cell culture.
Samples from patients are an extreme biohazard risk; testing should be conducted under maximum biological containment conditions.
Vaccine and treatment
No licensed vaccine for EVD is available. Several vaccines are being tested, but none are available for clinical use.
Severely ill patients require intensive supportive care. Patients are frequently dehydrated and require oral rehydration with solutions containing electrolytes or intravenous fluids.
No specific treatment is available. New drug therapies are being evaluated.